345 related articles for article (PubMed ID: 32250471)
1. Mucosal concentrations of N-acetyl-5-aminosalicylic acid related to endoscopic activity in ulcerative colitis patients with mesalamine.
Fukuda T; Naganuma M; Takabayashi K; Hagihara Y; Tanemoto S; Nomura E; Yoshimatsu Y; Sugimoto S; Nanki K; Mizuno S; Mikami Y; Fukuhara K; Sujino T; Mutaguchi M; Inoue N; Ogata H; Iwao Y; Abe T; Kanai T
J Gastroenterol Hepatol; 2020 Nov; 35(11):1878-1885. PubMed ID: 32250471
[TBL] [Abstract][Full Text] [Related]
2. Measurement of colonic mucosal concentrations of 5-aminosalicylic acid is useful for estimating its therapeutic efficacy in distal ulcerative colitis: comparison of orally administered mesalamine and sulfasalazine.
Naganuma M; Iwao Y; Ogata H; Inoue N; Funakoshi S; Yamamoto S; Nakamura Y; Ishii H; Hibi T
Inflamm Bowel Dis; 2001 Aug; 7(3):221-5. PubMed ID: 11515848
[TBL] [Abstract][Full Text] [Related]
3. Influence of Pharmaceutical Formulation on the Mucosal Concentration of 5-Aminosalicylic Acid and N-Acetylmesalamine in Japanese Patients with Ulcerative Colitis.
Yamamoto Y; Masuda S; Nakase H; Matsuura M; Maruyama S; Hisamatsu T; Suzuki Y; Matsubara K
Biol Pharm Bull; 2019 Jan; 42(1):81-86. PubMed ID: 30369547
[TBL] [Abstract][Full Text] [Related]
4. Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis.
Frieri G; Giacomelli R; Pimpo M; Palumbo G; Passacantando A; Pantaleoni G; Caprilli R
Gut; 2000 Sep; 47(3):410-4. PubMed ID: 10940280
[TBL] [Abstract][Full Text] [Related]
5. 5-ASA colonic mucosal concentrations resulting from different pharmaceutical formulations in ulcerative colitis.
D'Incà R; Paccagnella M; Cardin R; Pathak S; Baldo V; Giron MC; Sturniolo GC
World J Gastroenterol; 2013 Sep; 19(34):5665-70. PubMed ID: 24039359
[TBL] [Abstract][Full Text] [Related]
6. Mucosal 5-aminosalicylic acid concentration, drug formulation and mucosal microbiome in patients with quiescent ulcerative colitis.
Olaisen M; Spigset O; Flatberg A; Granlund AVB; Brede WR; Albrektsen G; Røyset ES; Gilde B; Sandvik AK; Martinsen TC; Fossmark R
Aliment Pharmacol Ther; 2019 May; 49(10):1301-1313. PubMed ID: 30895635
[TBL] [Abstract][Full Text] [Related]
7. [Localization of salazopyrin in colonic mucosa patients with ulcerative colitis].
Kitano A; Tabata A; Obayashi M; Nakagawa M; Yasuda K; Fukushima R; Okabe H; Tomobuchi M; Nakamura S; Kashima K
Nihon Shokakibyo Gakkai Zasshi; 1993 Feb; 90(2):124-33. PubMed ID: 8096555
[TBL] [Abstract][Full Text] [Related]
8. The systemic load and efficient delivery of active 5-aminosalicylic acid in patients with ulcerative colitis on treatment with olsalazine or mesalazine.
Støa-Birketvedt G; Florholmen J
Aliment Pharmacol Ther; 1999 Mar; 13(3):357-61. PubMed ID: 10102969
[TBL] [Abstract][Full Text] [Related]
9. Effect of Long-Term Mesalamine Therapy on Cancer-Associated Gene Expression in Colonic Mucosa of Patients with Ulcerative Colitis.
Bajpai M; Seril DN; Van Gurp J; Geng X; Alvarez J; Minacapelli CD; Gorin S; Das KK; Poplin E; Cheng J; Amenta PS; Das KM
Dig Dis Sci; 2019 Mar; 64(3):740-750. PubMed ID: 30478770
[TBL] [Abstract][Full Text] [Related]
10. Timing for dose-down of 5-ASA depends on mucosal status with ulcerative colitis.
Takahashi F; Tominaga K; Kanamori A; Takenaka K; Hoshino A; Sugaya T; Nakano M; Hiraishi H
Scand J Gastroenterol; 2016 Jul; 51(7):827-34. PubMed ID: 26853910
[TBL] [Abstract][Full Text] [Related]
11. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
Feagan BG; Macdonald JK
Cochrane Database Syst Rev; 2012 Oct; 10():CD000544. PubMed ID: 23076890
[TBL] [Abstract][Full Text] [Related]
12. Systemic absorption of 5-aminosalicylic acid in patients with inactive ulcerative colitis treated with olsalazine and mesalazine.
Karamanolis DG; Papatheodoridis GV; Xourgias V
Eur J Gastroenterol Hepatol; 1996 Nov; 8(11):1083-8. PubMed ID: 8944370
[TBL] [Abstract][Full Text] [Related]
13. Randomized clinical trial: pharmacokinetics and safety of multimatrix mesalamine for treatment of pediatric ulcerative colitis.
Cuffari C; Pierce D; Korczowski B; Fyderek K; Van Heusen H; Hossack S; Wan H; Edwards AY; Martin P
Drug Des Devel Ther; 2016; 10():593-607. PubMed ID: 26893546
[TBL] [Abstract][Full Text] [Related]
14. Importance of the Evaluation of N-Acetyltransferase Enzyme Activity Prior to 5-Aminosalicylic Acid Medication for Ulcerative Colitis.
Matthis AL; Zhang B; Denson LA; Yacyshyn BR; Aihara E; Montrose MH
Inflamm Bowel Dis; 2016 Aug; 22(8):1793-802. PubMed ID: 27416043
[TBL] [Abstract][Full Text] [Related]
15. Correlation of Fecal Markers with Magnifying Endoscopic Stratification in Patients with Ulcerative Colitis Who Are in Clinical Remission.
Mine S; Takeshima F; Akazawa Y; Matsushima K; Minami H; Yamaguchi N; Ohnita K; Isomoto H; Nakao K
Digestion; 2018; 97(1):82-89. PubMed ID: 29393146
[TBL] [Abstract][Full Text] [Related]
16. Mucosal Healing in Ulcerative Colitis--When Zero is Better.
Boal Carvalho P; Dias de Castro F; Rosa B; Moreira MJ; Cotter J
J Crohns Colitis; 2016 Jan; 10(1):20-5. PubMed ID: 26438714
[TBL] [Abstract][Full Text] [Related]
17. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Wang Y; Parker CE; Bhanji T; Feagan BG; MacDonald JK
Cochrane Database Syst Rev; 2016 Apr; 4(4):CD000543. PubMed ID: 27101467
[TBL] [Abstract][Full Text] [Related]
18. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Feagan BG; Macdonald JK
Cochrane Database Syst Rev; 2012 Oct; 10():CD000543. PubMed ID: 23076889
[TBL] [Abstract][Full Text] [Related]
19. Fecal Calprotectin in Assessing Endoscopic and Histological Remission in Patients with Ulcerative Colitis.
Mak WY; Buisson A; Andersen MJ; Lei D; Pekow J; Cohen RD; Kahn SA; Pereira B; Rubin DT
Dig Dis Sci; 2018 May; 63(5):1294-1301. PubMed ID: 29468374
[TBL] [Abstract][Full Text] [Related]
20. Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion.
Staerk Laursen L; Stokholm M; Bukhave K; Rask-Madsen J; Lauritsen K
Gut; 1990 Nov; 31(11):1271-6. PubMed ID: 2253912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
